DNLI
Denali Therapeutics Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders +8.3% ·
aandelenstroom +17.4% ·
netto nieuwe posities +7.7%
— formule
Brede accumulatie — stijgende aandelen bij meer houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q1 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 97 | +6 | 103.66M | $2.65B | +11 | −4 |
| Q1 2026 | 93 | +4 | 96.77M | $1.85B | +11 | −8 |
| Q4 2025 | 89 | 0 | 110.68M | $1.83B | +1 | — |
| Q3 2025 | 19 | 0 | 67.26M | $976.61M | — | −1 |
| Q2 2025 | 17 | +1 | 74.76M | $1.05B | +2 | −1 |
| Q1 2025 | 13 | +1 | 44.98M | $611.55M | +2 | −1 |
| Q4 2024 | 12 | -1 | 38.31M | $780.78M | — | −1 |
| Q3 2024 | 12 | 0 | 34.10M | $993.27M | +1 | −1 |
| Q2 2024 | 12 | — | 35.56M | $825.78M | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Baillie Gifford ✦ | 12.09M | -1.8% | $164.36M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 12.09M | -1.8% | $164.36M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 3 | Baillie Gifford ✦ | 12.09M | -1.8% | $164.36M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 4 | Baillie Gifford ✦ | 12.09M | -1.8% | $164.36M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 11.41M | +15.9% | $155.11M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 11.41M | +15.9% | $155.11M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 11.41M | +15.9% | $155.11M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 11.41M | +15.9% | $155.11M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Wellington Management ✦ | 11.41M | +15.9% | $155.11M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Wellington Management ✦ | 11.41M | +15.9% | $155.11M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | Wellington Management ✦ | 11.41M | +15.9% | $155.11M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | State Street Global Advisors ✦ (passief) | 4.46M | -1.9% | $60.64M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 4.37M | +42.8% | $59.37M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 4.37M | +42.8% | $59.37M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Norges Bank ✦ (passief) | 3.05M | +186.0% | $41.43M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | Geode Capital Management ✦ (passief) | 3.04M | +3.5% | $41.30M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | Geode Capital Management ✦ (passief) | 3.04M | +3.5% | $41.30M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Marshall Wace ✦ | 2.19M | +22.3% | $29.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 19 | Millennium Management ✦ | 1.49M | +269.4% | $20.30M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 20 | Fisher Asset Management ✦ | 1.36M | +72.2% | $18.56M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 21 | Citadel Advisors ✦ | 1.17M | +40.9% | $15.90M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 22 | Citadel Advisors ✦ | 1.17M | +40.9% | $15.90M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 23 | Renaissance Technologies ✦ | 173.10K | Nieuw | $2.35M | 0.0% | New | 1 | SEC ↗ |
| 24 | Two Sigma Investments ✦ | 102.40K | -43.1% | $1.39M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 25 | D. E. Shaw & Co. ✦ | 78.22K | Nieuw | $1.06M | 0.0% | New | 1 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Renaissance Technologies | $2.35M | 0.0% |
| D. E. Shaw & Co. | $1.06M | 0.0% |
Verlaten
| Point72 Asset Management | $11.18M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 265 houders, 147.10M aandelen, $2.60B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 2.86K aand · $71,625
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie